Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jade Biosciences Appoints Edward R. Conner, M.D.
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript
Jade Biosciences to Participate in Upcoming Conferences
Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
Jade Biosciences Announces $45 Million Private Placement
Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect?
What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock
Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should Know
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
Jade Biosciences to Participate in Upcoming Conferences
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
Jade Biosciences Announces $135 Million Private Placement
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
Jade Biosciences to Participate in Upcoming Conferences
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jade Biosciences to Participate in Two Upcoming Investor Conferences
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update